AU3203489A - Lipophilic polyamines useful for treating hypercholesterolemia - Google Patents

Lipophilic polyamines useful for treating hypercholesterolemia

Info

Publication number
AU3203489A
AU3203489A AU32034/89A AU3203489A AU3203489A AU 3203489 A AU3203489 A AU 3203489A AU 32034/89 A AU32034/89 A AU 32034/89A AU 3203489 A AU3203489 A AU 3203489A AU 3203489 A AU3203489 A AU 3203489A
Authority
AU
Australia
Prior art keywords
bis
ethanediamine
alkyl
aminoethyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32034/89A
Inventor
James W. Aiken
Charles H. Spilman
Edward W. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU3203489A publication Critical patent/AU3203489A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C07C2601/20—Systems containing only non-condensed rings with a ring being at least seven-membered the ring being twelve-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Description

LIPOPHILIC POLYAMINES USEFUL FOR TREATING HYPERCHOLESTEROLEMIA Field of Invention
This invention includes novel lipophilic polyamines which are useful for treating hypercholesterolemia and intermediates thereto. Background of the Invention
Cholesterol is probably the sole precursor of bile acids. During normal.,digestion, bile acids are secreted into the intestines. A major portion of the bile acid is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation system. Only very small amounts of bile acids are found in normal serum. Polymeric anion exchange resins are known to combine with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in partial removal of bile acids from the enterohepatic circulation by preventing their reabsorption. The increased fecal loss of bile acids leads to an increased oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in plasma cholesterol levels. Although excretion of bile acids produces an increase in hepatic synthesis of cholesterol, plasma cholesterol falls. These anion exchange resins are not systemically absorbed or digested although large quantities, up to 54 grams of the formulated resin per day for cholestyramine resin powder, are needed. These resins are not water soluble but are typically administered as an aqueous suspension. Colestipol-niacin therapy has recently been shown to significantly increase the regression of atherosclerosis in drug-treated subjects. D.H. Blankenhorn et al., JAMA, 1987, 257:3233-3240. Others have found cholestyramine reduces the incidence of coronary heart disease in treated patients. Lipid Research Clinics Program, JAMA, 1984, 251:351-364. With the positive effects of resins on coronary heart disease, one must balance the sometimes poor patient compliance. Therefore the medical community has recognized the need for new effective drugs of this type. S.M. Grundy, "Drugs Affecting Lipid Metabolism"; R. Paoletti, Ed., Springer Verlag: Berlin, 1987, pp. 34-41.
Information Disclosure
Some of the amino substituted hydrocarbons used to practice this invention are claimed in International Patent Application PCT/US86/ 02116 which has an International Publication Date of 23 April 1987. The International Application teaches these compounds are useful to treat phospholipid mediated conditions and diabetes.
The following are references to polyamine compounds similar to the compounds described herein, but not for the use of our invention.
CA 88:106267Z (German Patent, DE 2624528) discloses 1,2-Ethanedicimine, N-[2-(dimethylamino)ethyl]-N',N'-bis[2-[[2-(dimethylamino)-ethyl]methylamino]ethyl]-N-methyl-, useful as polyurethane foam materials. CA 105:197229X (Japanese Patent, J61146265) discloses Ethanaminium, N,N-bis(2-amino-ethyl)-N-(carboxymethyl)-2-(dodecylamino)-chloride, useful as an antimicrobial agent.
CA 74:99664g (German Patent, DE 2039214 and U.S. Patent 3,734,953) disclose Isophthalamic acid, N,N',N"-(nitrilotriethylene)-tris[5-nitro-, trimethyl ester, useful as a radiopaque agent.
CA87 :22564k (U.S. Patent 4,003,934) discloses 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'[2-(3,3-dimethylbicyclo[2.2.1]hept-2-yl)-1- [2-(3,3-dimethylbicyclo[2.2.1]hept-2-yl)ethyl]propyl]tetrahydrochloride, useful as an antimicrobial agent. CA67:21731n (U.S. Patent 3,291,808) discloses N-(dialkylaminoalkyl)-1,4-naphthalenediamines having useful antiparasitic properties.
CAl07:40601f (U.S. Patent 4,631,337) discloses hydrolyticallystable dense star polyamines, which are useful as calibration standards, high efficiency proton scavengers and in making size selective membranes.
CA54:26191g (U.S. Patent 2,874,174) discloses alkyl amides of N,N,N-tris(aminoalkyl)amines which are useful as binding agents for asphalt pavements. Summary of the Invention
A compound of the formula I wherein Z1 is
(a) -C3-C20-cycloalkyl substituted with zero or one =0,- C(O)OR11, -C(O)NH2, -CH=CH2, or ethylene ketal; (b) -C3-C20-alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -alkyl(C1-C12)-cycloalkyl(C3-C8);
(d) -benzyl substituted with zero, one, or two =O, -C(O)OR11,- C(O)NH2, -CH-CH2, -CF3, - phenyl or -benzyl-oxy; or (e) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH-CH2, -CF3, -phenyl or benzyl-oxy; wherein Y1 is
(a) -C(O)-, or
(b) absent; wherein X1 is
(a) -NR2-,
(b) -NR2R3, or
(c) -N(R2)2R3X4; wherein X4 is a pharmaceutically acceptable anion; wherein R1 is (a) -H,
(b) -C1-C4alkyl, (c) -benzyl, (d) -(CH2)p-N(R4)(R5), (e) -(CH2)p-N(R4)-Y1-R5, or
(f) when X1 is -NR2R3 or -N(R2)2R3X4, R1 is absent; wherein R2 is (a) -H, (b) -C1-C6alkyl, (c) -(CH2)m-N(R4)(R5), (d) -(CH2)m-N(R4)-Y1-R5, (e) -(CH2)m-O-(CH2)m-N(R4)(R5), or (f) -(CH2)m-NH-C(NH)-NH2; or when X1 is -NR2-, wherein R1 and R2 taken together cab be -(CH2)q- X3-(CH2)q-; wherein R3 is
(a) -CH3, or
(b) =O; wherein R4 is
(a) -H,
(b) -C1-C6alkyl,
(c) -benzyl,
(d) -phenyl,
(e) -(CH2)q-N(R6)(R7),
(f) -(CH2)q-N(R6)-Y1-R7, or
(g) -(CH2)q-N(R6)3X4; wherein R5 is
(a) -H,
(b) -Ci-Cgalkyl,
(c) -(CH2)r-N(R8)(R9), (d) -(CH2)r-N(R8)-Y1-R9> or
(e) -(CH2)r-N(R8)3X4; or wherein R4 and R5 taken together are - (CH2)q-X2- (CH2)q- ; wherein R6 , R7, R8, or R9 is each independently (a) -H, (b) -C3-C20cycloalkyl substituted with zero or one =0,- C(O)OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -C3-C20alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH=CH2, ethylene ketal or C=N;
(d) -alkyl (C1-C12)-cycloalkyl (C3-C8), (e) -benzyl substituted with zero, one, or two =0, -C(O)OR11,-
C(O)NH2, -CH=CH2, -CF3, -phenyl or benzyl-oxy;
(f) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(g) -(CH2)s-N(R10(R11; (h) -(CH2)s-N(R10)-Y1-R11; (i) amino acid residue, or (j) -(CH2)s-Het; or wherein R6 and R7 taken together are - (CH2)q-X2- (CH2)q- ; or wherein R8 and R6 taken together are - (CH2)q-X2- (CH2)q- ; wherein R10 or R11 is each independently
(a) -H,
(b) -C1-C6alkyl, or
(c) -(CH2)n-NH2; or wherein R10 and R11 taken together are - (CH2)q-X2- (CH2)q- ; wherein X2 is
(a) -O-,
(b) -NH-,
(c) -N(CH3)-, or
(d) -N-(CH2)q-NΗ2; wherein X3 is
(a) -O-,
(b) -S-,'
(c) -NH-, or (d) -N(CH3)-; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to three of the following:
(i) C1-C6alkyl, (ii) hydroxy, (iii) trifluoromethyl,
(iv) C1-C4alkoxy,
(v) halo, (vi) phenyl, (vii) phenyl C1-C4alkyl-, (viii) amino,
(ix) mono- or di- (C1-C4alkyl)amino, and (x) C1-C5alkanoyl; wherein n is zero to five, inclusive; wherein m, p, q, r or s is each independently one to ten, inclusive; with the provisos that:
1) If Z1 is C8-C20cycloalkyl, then one of the following must occur: a) R1 is other than -H, C1-C4alkyl, or benzyl; b) R2 is other than -H, -C1-C6alkyl or - (CH2)m-NH-C(NH) - NH2; c) when R1 is - (CH2)p-N(R4) (R5) or when R2 is -(CH2)m- N(R4)(R5) or -(CH2)m-O-(CH2)m-N(R4)(R5), then R4 is other than -H,- C1-C6alkyl, -benzyl, or -phenyl and R5 is other than -H or -C1-C6alkyl; d) when R4 is - (CH2)q-N(R6) (R7), then R6 and R7 are other than -H, -(CH2)3-NH2; e) R1 and R2 are not taken together; or f) R4 and R5 are not taken together; and
2) If Z1 is C10-C20alkyl, then Y1 is absent. A compound selected from the group consisting of:
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclododecyl; 1,2-Ethanediamine, N-(2-aminoethyl)-N'-cyclododecyl-; 1 ,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclohexyl-; 1,3-Propanediamine, N,N''-[2-(cyclododecylamino)ethylimino-di-2,1-ethanediyl]-bis-;
1,2-Ethanediamine, N-cyclododecyl-N',N'-bis-2-(dimethylamino)-ethyl-N-methyl-; Octadecanamide, N-[2[bis(2-aminoethyl)amino]ethyl]-; and
Octadecacamide, N,N'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]- bis-.
A method of treating hypercholesterolemia in an affected patient which comprises administering to said patient an effective amount for reducing serum cholesterol in said patient of a member selected from the group consisting of the free bases and pharmaceutically acceptable salts of a compound of formula I wherein Z1 is
(a) -C3-C20-cycloalkyl substituted with zero or one =0,- C(O)OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(b) -C3-C20-alkyl substituted with zero or one =0, -C(O)OR11,- (O)NH2, -CH=CH2, or ethylene ketal;
(c) -alkyl(C1-C12)-cycloalkyl(C3-C8);
(d) -benzyl substituted with zero, one, or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(e) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy; or
(f) a steroid of formula II; wherein A1 is (a) -(CH2)4-,
(b) -CH2-CH2-C(O)-CH-, or
(c) -CH2-CH2-CH(E1)-CH2-; wherein D1 is
(a) -hydrogen, or (b) -methyl; wherein E1 is
(a) -hydrogen, or
(b) -OF1; wherein F1 is (a) -H,
(b) -C1-C3alkyl, or
(c) -benzyl; wherein Y1 is (a) -C(O)-, or
(b) absent; wherein. X1 is
(a) -NR2-, (b) -NR2R3, or
(c) -N(R2)2R3X4; wherein X4 is a pharmaceutically acceptable anion; wherein R1 is (a) -H, (b) -C1-C4alkyl,
(c) -benzyl,
(d) -(CH2)p-N(R4)(R5),
(e) -(CH2)p-N(R4)-Y1-R5, or
(f) when X1 is -NR2R3 or -N(R2)2R3X4, R1 is absent; wherein R2 is
(a) -H,
(b) -C1-C6alkyl,
(c) -(CH2)m-N(R4)(R5),
(d) -(CH2)m-N(R4)-Y1-R5, (e) -(CH2)m-O-(CH2)m-N(R4)(R5), or (f) -(CH2)m-NH-C(NH)-NH2; or when X1 is -NR2-, wherein R1 and R2 taken together can be -(CH2)q- X3-(CH2)q-; wherein R3 is (a) -CH3, or (b) =O; wherein R4 is
(a) -H,
(b) -C1-C6alkyl, (c) -benzyl,
(d) -phenyl,
(e) -(CH2)q-N(R6)(R7),
(f) -(CH2)q-N(R6)Y1R7, or
(g) -(CH2)q-N(R6)3X4; wherein R5 is
(a) -H,
(b) -C1-C6alkyl,
(c) -(CH2)r-N(R8)(R9), (d) -(CH2)r-N(R8)-Y1-R9, or
(e) -(CH2)r-N(R8)3X4; or wherein R4 and R5 taken together are - (CH2)q-X2-(CH2)q-; wherein R6, R7, R3, or R9 is each independently (a) -H,
(b) -C3-C20cycloalkyl substituted with zero or one =0, C(O)-OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -C3-C20alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH=CH2, ethylene ketal or C≡N; (d) -alkyl (C1-C12)-cycloalkyl (C3-C8),
(e) -benzyl substituted with zero, one, or two -C(O)OR11, - C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(f) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy; (g) -(CH2)s-N(R10)(R11;
(h) -(CH2)s-N(R10)-Y1-R11; (i) amino acid residue; or (j) -(CH2)s-Het; or wherein R6 and R7 taken together are -(CH2)q-X2-(CH2)q-; or wherein R8 and R9 taken together are - (CH2)q-X2- (CH2)q-; wherein R10 or R11 is each independently
(a) -H,
(b) -C1-C6alkyl, or
(c) -(CH2)n-NH2; or wherein R10 and R11 taken together are - (CH2)q-X2- (CH2)q-; wherein X2 is
(a) -O-,
(b) -NH-,
(c) -N(CH3)-, or (d) -N-(CH2)q-NH2; wherein X3 is
(a) -O-,
(b) -S-,
(c) -NH-, or (d) -N(CH3)-; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to three of the following:
(i) q-Cgalkyl, (ii) hydroxy,
(iii) trifluoromethyl, (iv) C1-C4alkoxy,
(v) halo, (vi) phenyl, (vii) phenyl C1-C4alkyl-,
(viii) amino,
(ix) mono- or di- (C1-C4alkyl) amino, and (x) C1-C5alkanoyl; wherein n is zero to five, inclusive; wherein m, p, q, r or s is each independently one to ten, inclusive; provided that the compound is other than:
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclohexyl-; 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-1,4-dioxaspiro-4.5-dec-8-yl-; 1,2-Ethanediamine, N,N-bis-2-(1,4-dioxaspiro-4.5-dec-8-ylamino)-ethyl-;
N,N-Bis-(2-aminoethyl)-N'-phenylmethyl-1,2-ethanediamine;
N-(2-aminoethyl)-N'-(phenylmethyl)-N-(2-((phenylmethyl)amino)ethyl); or N[[2-[-Bis(2-aminoethyl)amino]ethyl]benzamide. Detailed Description of the Invention
By "amino acid residue" is meant the naturally-occurring amino acids such as: glycine, alanine, valine, leucine, isoleucine, phenylalanine, lysine, proline, tryptophan, methionine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, ornithine, and histidine, and synthetic derivatives thereof. These compounds may be in L or D configuration and are well known and readily available to those skilled in the art.
Unless otherwise indicated, in the above description and throughout this document: (a) the parenthetical term (Cn-Cm) is inclusive such that a compound of (C1-C4) would include compounds of 1, 2, 3 and 4 carbons and their isomeric forms.
The scope of this invention includes the pharmacologically acceptable acid salts of the disclosed compounds. Acid salts are formed by reacting the compounds described herein with the appropriate acid in a suitable solvent. Suitable acids for this purpose include hydrochloric, sulfuric, phosphoric, hydrobromic, hydroiodic, acetic, lactic, citric, succinic, benzoic, salicylic, palmoic, cyclohexansulfamic, methanesulfonic, naphthalenesulfonic, p-toluenesulfonic, maleic, fumaric, or oxalic.
Some of the compounds used to practice this invention are prepared by the methods and processes taught in United States Patent Application Serial Number 117,851; filed 16 June 1987. This application is herein incorporated by reference. The methods and processes used to prepare amino cyclic hydrocarbons are described on pages 18 to 24 and the related charts and specific examples are described on pages 28 to 114.
Charts A, G, H, & I (Generic Charts) The compounds A-3, A-4 and A-5 are made from commercially available ketones or aldehydes A-1 (or readily synthesized ketones or aldehydes) and commercially available amines, by reductive amination methods (See R.F. Borch, M.D. Berstein, H.D. Durst, JACS , 93:2897-2904, 1971; and J.H. Billman, and A.O. Diesing, J.O.C, 22:1068-1070, 1957).
The compounds G-3, G-5 and G-7 are made from esters or activated esters G-1, G-4 and G-6, and amines G-2, using the procedures set forth in A.L.J. Bechmith, in "The Chemistry of Amides"; J. Zuhicky, Ed., Interscience, New York, Chapter 2, 1970. The compound A-5 is elaborated by reacting free amines 1-1 (A-5) and H-1 (A-5) with unsaturated esters J-2 or nitriles H-2 for chain extended compounds 1-3 and H-3, respectively. The intermediate H-3 is then reduced to the corresponding final amine H-4. The intermediate 1-3 is further reacted with amine 1-4 to yield the final product 1-5. 1-5 is reduced to yield another final product 1-6.
Chart B (Scheme 1)
While employing commercially available B-1 and only 1.2 equivalents of amine B-2, B-3 and dialkylated amine B-4 are isolated.
These polar compounds are separated by chromatography on commercially available silica gel when eluting with chloroform/methanol/ammonium hydroxide.
Chart B (Scheme 2) For the formation of compounds B-6, 2 equivalents of amine (B-2) to ketone (B-5) is optimum for the formation of mono-adducts. When 2 equivalents of amine B-2 are reacted with one equivalent of ketone B-5, a statistical 1:2:1 ratio of B-6:B-7:B-8 are formed. Further treatment of amine B-2 with 4 equivalents of ketone B-5 affords the tris-adduct B-8, with no trace of mono-adduct B-6.
Chart B (Scheme 3) For the formation of compound B-10, 2 equivalents of amine to ketone is optimum for the formation of mono-adducts.
Chart B (Schemes 4, 5 and 6) Additional analogs B-12, B-13, B-15, B-16, and B-18 are also synthesized by this method. The rings of B-15 and B-16 contain functional groups. The compound B-14 and B-17 are commercially available.
Chart B (Schemes 7, 8) Two open-chain analogs, B-20 and B-22, also are produced by this method.
Chart C (Reductive amination of aldehydes) The compound C-3, wherein R is pentadecyl, is formed by hydrogenating the imine derived from hexadecyl aldehyde and the amine C-2. W.H. Emerson, Org. React. 1948, 4, 174-255. For the synthesis of imines see, S. Dayagi and Y. Degani, "The Chemistry of Carbon-Nitrogen Double Bond", S. Patai, Ed., Interscience: New York, 1970: Chapter 2. Other adducts as listed in the Table for Chart C are synthesized by the same method. The compound C-3 wherein R is (Bn-O)2-phenyl- is produced by reducing the intermediate imine with sodium borohydride in methanol. J.H. Billman and A.C. Diesing, J. Org. Chem. 1957, 22, 1068-1070.
Chart D (Scheme 1) Amide derivatives of simple amines are readily available by a number of methods. A.L.J. Beckwith, in "The Chemistry of Amides"; J. Zubicky, Ed., Interscience: New York, 1970: Chapter 2. Treatment of ester D-1 on a steam bath with amine D-2 yields the amide D-3 and the diamide D-4, that are separated by column chromatography. Chart D (Schemes 2 and 3)
Other acylating agents such as acid chlorides D-5 and D-7 when treated with amine D-2, afford none of the monoacylated material.
Chart D (Schemes 4 and 5) A method found to produce at least a statistical product distribution from polyamines consists of increasing the reaction dilution and decreasing the reactivity of the acylating agent. A.R. Jacobson, et al., J. Org. Chem. 1987, 52, 2592-2594. The compound D-9 and diamine D-10 yield mainly D-11 and some diacylated D-12. Anhydride D-9 and amine D-2 form the monoacylated compound D-13 and diacylated D-14.
Chart E (Schemes 1 and 2) [Amine portion modification] [Amine chain extension] Selective Michael addition of 2 equivalents of acrylonitrile of E-2 to the primary amines of E-1, prepared as the compound B-16 In Chart B, form the compound E-3. Reduction of the nitriles with lithium aluminum hydride (LAH) produces the hexamine E-4. In a similar fashion, methyl acrylate E-5 and amine E-1 produce the diester E-6. Following chemistry developed to produce starburst or arborol compounds (D.A. Tomalia, et al., Polymer Journal 1985, 17, 117-132; G.R. Newkome, et al., J. Am. Chem. Soc. 1986, 108, 849-850.), the diester E-6 is treated with excess ethylenediamine to yield the amine extended analog E-7. Chart F (Schemes 1, 2 and 3)
The Eschweiler-Clark reaction affords penta-alkylated amine F-3. S.H. Pine and B.L. Sanchez, J. Org. Chem. 1971, 36, 829-832; M.L. Moore, Org. React. 1949, 5, 301-330. The two less hindered amines of F-3 are selectively alkylated with 2 equivalents of methyl iodide to form F-4. The Eschweiler-Clark reaction is also employed to produce analog F-6.
Biological studies demonstrate the utility of this invention. Male SEA Japanese quail, approximately four to six weeks of age, were reared at Miles Quail Farm, Gobies, Michigan. Prior to drug testing, birds were randomly distributed into 10-15 groups of 10 quail each. They were housed individually in 10 cage units and fed a commercial diet (Purina Game Bird Layena, Ralston Purina Co., St. Louis, MO) mixed with 0.5% cholesterol and 1% peanut oil (diet D1) for 14 days. Compounds were mixed into 2.4 kg of the diet by a special mixer (Hobart A-200) for 20 minutes. Control groups received diet D1 alone, and positive control groups received diet D1 mixed with colestipol hydrochloride) at an amount to provide a dose of 750 mg/kg/day. After two weeks on the diets, each bird was bled from the right jugular vein and serum samples were obtained after low speed centrifugation. Food intake was determined for each group by subtracting the weight of diet remaining at the end of the experiment from the weight of the starting diet.
Normal male rats, UPJ:TUC(SD)spf, weighing 100-110 grams were evenly distributed by weight into groups of ten. The animals were housed in stainless steel cages with five rats in each cage. Food and water were allowed ad libitum. The rats were placed on a defined diet containing 1% (wt/wt) cholesterol. The diet was in powder form and was presented to the rats in feed jars fitted with stainless steel guards to prevent loss of feed. Compounds to be tested were mixed into this diet using a Hobart A-200 mixer. Colestipol hydrochloride administered at daily doses of 500 and/or 1000 mg/kg is used as the positive control in this assay. After seven days on the diet with or without test compound, the rats were anesthetized with Cyclopal sodium and bled from the right jugular vein. Serum samples were obtained after low speed centrifugation.
Beta- and alpha-lipoproteins were isolated from individual serum samples using PEG- 8000 and glycine buffer, pH 9. Three hundred microliters of serum were mixed with 300 microliters of solution A (20 gram of PEG- 8000 + 100 ml of glycine buffer, pH 9) using a Micromedic automatic pipette. Samples were allowed to stand at room temperature for 10 minutes and were then centrifuged for 20 minutes at 2000 × g at 4ºC. The beta-lipoprotein pellet was dissolved in 300 microliters of solution B (10 ml Triton X-100 + 1000 ml Milli Q water). Cholesterol, triglycerides and total protein in alpha- and beta-lipoproteins were measured using the Demand Autoanalyzer Aystem Model AU 500 (Cooper Biomedical Inc.) and Worthington Demand Enzymatic reagents.
All data were statistically analyzed using a one-way classification design. All values were transformed to logarithms to achieve more homogeneous within-group variances. The mean response for each test compound was compared with the mean observed in the animals fed the cholesterol-containing diet alone by the LSD test. The compound, N,N-Bis-2-(cyclododecylamino)ethyl-1,2-ethanediamine, is about 15 times more potent than colestipol hydrochloride; the effect of 50 mg/kg/day was similar to the effect of 750 mg/kg/day of colestipol hydrochloride.
The results of studies performed using SEA quail are shown in Table 1. The compound, N,N-bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine administered at 150 mg/kg/day, is about fifteen times more potent than colestipol hydrochloride; the effect of 150 mg/kg/-day of N,N-bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine was similar to the effect of 2250 mg/kg/day colestipol hydrochloride.
The results of studies performed in cholesterol-fed rats are shown in Table 2. The compound N,N-bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine administered at 150 mg/kg/day is about five times more potent than colestipol hydrochloride; the effect of 150 mg/kg/day of N,N-bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine was about half-way between the effects of 500 and 1000 mg/kg/day of colestipol hydrochloride. Also shown in Table 2 are the results using N,N-bis[2-(cyclododecylamino)ethyl]-1,2-ethanediamine. This compound is about eight times more potent than colestipol hydrochloride; the effect of 60 mg/kg/day of N,N-bis[2-(cyclododecylamino)ethyl]-1,2-ethanediamine is very similar to the effect of 500 mg/kg/day of colestipol hydrochloride. In hyperlipidemic patients with serum cholesterol values above 200 mg per 100 ml, the compounds used to practice the present invention lower cholesterol levels when the dose of the active ingredient varies from about 0.5 to about 5 gm, administered from one to three times daily. The preferred compounds of the present invention are:
N,N-Bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine; N,N-Bis-2-(cyclododecylamino)ethyl-1,2-ethanediamine; N,N-Bis(2-aminoethyl)-N'-cyclododecyl-1,2-ethanediamine; N'-Cyclododecyl-N,N-bis-2-(cyclododecylamino)ethyl-1,2-ethanediamine; and
N,N-Bis(2-aminoethyl)-N'-hexadecyl-1,2-ethanediamine. The following compounds of the present invention are useful as Intermediates:
N,N-Bis(2-aminoethyl)-N'-cyclohexyl-1,2-Ethanediamine; N,N-Bis(2-aminoethy1)-N'-1,4-dloxaspiro-4.5-dec-8-yl-1,2- ethanediamine;
N,N-Bis-2-(1,4-dioxaspiro-4.5-dec-8-ylamino)ethyl-1,2-ethanediamine; N,N-Bis-(2-aminoethyl)-N'-phenylmethyl-1,2-ethanediamine;
N-(2-aminoethyl)-N'-(phenylmethyl)-N-(2((phenylmethyl)amino) ethyl-1,2-ethanediamine; and
N[2E-bis(2-aminoethyl)amino]ethyl]benzamide. Without further elaboration, It is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compositions of this invention and are to be construed as merely illustrative and not limitations of the preceding disclosure in any way whatsoever. Example 1 Capsule
One thousand two-piece hard gelatin capsules for oral use, each containing 500 mg of N,N-bis(2-cyclododecylamino)ethyl-1,2-ethanediamine are prepared from the following ingredients: N,N-bis(2-cyclododecylamino)ethyl- 1,2-ethanediamine 500 gm
Talc, USP 50 gm
Magnesium stearate, USP 2 gm
The finely powdered ingredients are mixed thoroughly, then filled into hard gelatin capsules of appropriate size. Two capsules are taken four times a day with meals and an evening snack to lower blood cholesterol in hypercholesterolemic patients. Example 2 Powder packets
Ten thousand powder packets, each containing 1.25 gm of N,N-bis(2-cyclododecylamino)ethyl-1,2-ethanediamine hydrochloride are prepared from the following:
N,N-bis (2-cyclododecylamino)ethyl- 1,2-ethanediamine hydrochloride 12,500 gm
One or two packets emptied and stirred into water, fruit or vegetable juices, skimmed milk, or mixed with cereal, applesauce or other food, is given four times daily. Example 3 Oil base suspension
One thousand ml of an oral suspension containing 750 mg of N,N-bis(2-cyclododecylamino)ethyl-1,2-ethanediamine in each 5 ml is prepared from the following ingredients:
N,N-bis(2-cyclododecylamino)ethyl- 1,2-ethanediamine 150 gm
Oil base, qs 1,000 ml The oil base consists of equal parts of soybean oil and purified linseed oil gelled with 1% aluminum monostearate. Each 5 ml of base supplies 1.1 ml of linolenic acid. One or two teaspoonsful (5 or 10 ml) is administered three times a day with meals. Example 4 Aqueous dispersion
An aqueous oral dispersion containing In each tablespoon (15 ml) 1000 mg of N,N-bis(2-cyclododecylamino)ethyl-1,2-ethanediamine is prepared from the following materials: N,N-bis(2-cyclododecylamino)ethyl- 1,2-ethanediamine 1,000 gm
Pectin, NF 100 gm
Deionized water, qs 15,000 ml
One tablespoon (15 ml) is given three times a day, with meals, to lower blood cholesterol in hypercholesterolemic individuals. Example 5 Powder packets
Five thousand powder packets, each containing 2.5 gm of N,N-bis(2-cyclododecylamino)ethyl-1,2-ethanediamine hydrochloride, are prepared from 12,500 gm of the compound. One packet emptied a dispersed into an aqueous vehicle such as water, fruit or vegetable juice, skimmed milk, or the like is taken four times daily to reduce the serum cholesterol levels in hypercholesterolemic patients. Example 6
Similar tablets, capsules, powder packets, oil base suspensions and aqueous dispersions useful in reducing hypercholesterolemia are prepared using procedures analagous o those in Examples 2 through 6 utilizing the other compounds used to practice the present invention. Example 7 N,N-Bis(2-aminoethyl)-N'-cyclopentadecyl-1,2-ethanediamine (Formula B-3) and N,N-bis-2-(cyclopentadecylamino)ethyl-1,2-ethanediamine (Formula B-4). Refer to Chart B (Scheme 1)
Amine B-2 (39.1 g), methanol (800 ml), acetic acid (62 ml, and cyclopentadecanone B-1 (50.0 g) are combined. After 1.5 h, sodium cyano-borohydride (14.7 g) is added via Gooch tubing and the reaction is continued at room temperature. After 18 h the reaction is evacuated in vacuo. A solution of 10% sodium hydroxide (200 ml) is added to the solid. The aqueous portion is extracted with methylene chloride (3 × 400 ml). The combined organic fractions are dried, and concentrated in vacuo to 80.71 g. The crude material is chromato graphed on silicon dioxide (2.5 kg) and eluted with chloroform/-methanol/ammonium hydroxide (10/4/1) to yield fraction A (23.84 g) and the first title product (38.0 g), which is similar by NMR to material prepared previously. Fraction A is rechromatographed in the same solvent system to yield the second title product (8.0 g).
Physical characteristics of the second title product are as follows:
1H NMR (CDCl3): δ 1.22-1.70, 2.45-2.80.
13C NMR (CDCL3)ppm: 58.4, 57.3, 54.9, 45.5, .32.9, 27.6, 26.9, 26.8, 26.64, 26.57, 23.7.
IR (neat): 3299, 2929, 1460, 1365 cm-1.
Chemical Ionization (NH3) MS for C36H74N4: 562, 324, 312, 251, 238.
Anal. Found: C, 76.61; H, 13.42; N, 9.87. Example 8 N,N-Bis(2-aminoethyl)-N'-cyclododecyl-1,2-ethanediamine (Formula B-6). Refer to Chart B (Scheme 2) Amine B-2 (8.2 g), methanol (100 ml), acetic acid (26 ml), and ketone B-5 (5.1 g) are combined and the pH is measured at 5. After 2 h, sodium cyano-borohydride (1.85 g) is added and the reaction is continued at room temperature. After 24 h the reaction is evaporated in vacuo. To the solid is added 10% sodium hydroxide (25 mL), pH = 8. Additional sodium hydroxide is added. The aqueous portion is extracted with chloroform (3 × 100 ml). The combined organic fractions are extracted with 10% sodium hydroxide, dried, and concentrated in vacuo. The crude material is chromatographed on silicon dioxide (300 g) and eluted with chloroform/methanol/ammonium hydroxide (10/4/1) to yield 6.9 g of material contaminated with solvent. Bulb to bulb distillation of the crude material in a Kugelrohr apparatus affords the title product (4.74 g). Physical characteristics are as follows: Bp: 180-200ºC at 0.08 mm. 1H NMR (CDCI3): δ 1.22-1.60, 2.47-2.70.
13C NMR (CDCI3) ppm: 57.9, 55.3, 54.9, 45.5, 40.0, 29.4, 25.0, 24.5, 23.1, 23.0, 20.9. IR (neat): 3363, 3283, 2932, 1658, 1470, 1446, 1347 cm-1.
MS for C18H40N4, (m/e): 313, 282, 278, 209, 196, 116, 99, 87. Anal. Found: C, 69.06; H, 13.06; N, 17.93. Example 9 N,N-Bis-2-(cyclododecylamino)ethyl-1,2-ethanediamine (Formula B-7). Refer to Chart B (Scheme 2). Amine B-2 (18.28 g, methanol (900 ml), acetic acid (60 ml), and ketone B-5 (45.9 g) are combined and the pH of the reaction is between 5 and 6. After 0.5 h, sodium cyano-borohydride (16.65 g) is added portion-wise over 20 min and the reaction is continued at room temperature. After 19 h the reaction is evacuated in vacuo. A solution of 20% sodium hydroxide is added to the solid to bring the mixture to pH = 12. The aqueous portion is extracted with chloroform (4 × 250 ml). The combined organic fractions are concentrated in vacuo. The crude material is chromatographed on silicon dioxide (2 kg) and eluted with chloroform/methanol (1/1) followed by chloroform/methanol/ammonium hydroxide (10/4/0.5), and finally with a solvent ratio of 10:4:1 to yield B-8 (14.34 g), a mixture of B-8 and B-7 (243.8 g), B-7 (8.49 g), followed by B-6 (9.05 g). The mixture of B-7 and B-8 Is rechromatographed to yield B-8 (3 g), a mixed fraction (5.1 g), and B-7 (15.9 g). The large fraction of B-7 is dissolved in hexane, filtered, and evaporated In vacuo. Physical characteristics are as follows: 1H NMR (CDCl3): δ 1.22-1.60, 2.47-2.70. IR (neat): 3357, 3293, 2931, 1470, 1444 cm-1.
MS for C30Hg2N4, (m/e) : 448, 282, 270, 209, 196, 99. Chemical Ionization MS for C30H62N4: 479. Anal. Found: C, 75.26; H, 13.17; N, 11.74. Example 10 N-(2-aminoethyl)-N'-cyclododecyl-1,2-ethanediamine (Formula B-10). Refer to Chart B (Scheme
3).
Amine B-9 (5.76 g, methanol (100 ml), acetic acid (26 ml), and ketone B-5 (5.1 g) are combined and the pH is measured at 4. After 2 h, sodium cyano-borohydride (1.85 g) is added and the reaction is continued at room temperature. After 24 h the reaction is quenched with 10% sodium hydroxide (25 ml), pH = 8, and additional sodium hydroxide is added to bring the pH of the mixture to 12. The aqueous portion is extracted with chloroform (3 × 100 ml) . The combined organic fractions are extracted with 10% sodium hydroxide, dried, and concentrated in vacuo. The crude material is chromatographed on silicon dioxide (300 g) and eluted with chloroform/methanol/ammonium hydroxide (10/4/1) to yield 5.2 g of material contaminated with solvent. Bulb to bulb distillation of the product in a Kugelrohr apparatus affords the title product (4.57 g). Physical characteristics are as follows: Bp: 160-180ºC at 0.08 mm. 1H NMR (CDCl3): δ 1.20-1.60, 2.51-2.81. 13C NMR (CDCI3) ppm: 54.8, 52.6, 49.8, 47.0, 41.9, 29.5, 24.9, 24.4, 23.2, 23.1, 20.9.
IR (neat): 3295, 2931, 1657, 1470, 1445, 1346, 1116 cm-1. MS for C16H35N3, (m/e) : 270, 252, 239, 209, 197, 196, 182, 73. Anal. Found: C, 71.07; H, 13.15; N, 15.51. Example 11 N'-Cyclododecyl-N,N-bis-2-(cyclododecylamino)- ethyl-1,2-ethanediamine (Formula B-8). Refer to
Chart B (Scheme 2).
Amine B-2 (18.28 g), methanol (900 ml), acetic acid (60 ml), and ketone B-5 (91.15 g) are combined. After 0.5 h, sodium cyanoborohydride (31.4 g) is added via Gooch tubing over several hours.
The reaction is continued at room temperature for 18 h. The mixture is concentrated in vacuo and 20% sodium hydroxide (200 m) is added.
The aqueous portion is extracted with hexane (3 × 200 ml) and the organic portions are combined and concentrated to 40.9 g. The aqueous portion is then extracted with chloroform (3 × 200 ml) and the organic fractions are combined and concentrated to 69.4 g. Since the TLC of both organic fractions shows a mixture of compounds, the material is combined and chromatographed on 2.5 kg of silicon dioxide eluting first with chloroform/methanol followed by chloroform/-methanol/ammonium hydroxide (10/4/1). The first compound eluted is identified as cyclododecanol (21.98 g). The second compound eluted is B-8 (66.9 g). The material is heated in a Kugelrohr oven (up to
100°C, at 0.1 mm) to remove solvent and the material upon cooling slowly solidifies yielding 59.01 g of the title product. Physical characteristics are as follows:
1H NMR (CDCI3): δ 1.24-1.60, 1.70,, 2.51-2.70.
13C NMR (CDCI3) ppm: 55.3, 54.8, 45.2, 29.0, 25.1, 24.6, 22.9, 22.8, 20.6.
IR (mineral oil mull): 3298, 2970, 1475, 1445, 1377, 1348, 1125, 1120, 1061, 793, 774, 741, 721 cm-1.
MS for C42H84N4, (m/e): 643, 448, 436, 253, 196. Anal. Found: C, 77.83; H, 12.77; N, 8.70. Corrected for 0.22% water. Example 12 N,N-Bis(2-aminoethyl)-N'-cyclohexyl-1,2-Ethanediamine (Formula B-12). Refer to Chart B (Scheme 4). The amine B-2 (14.9 g, 15.5 ml), methanol (184 ml), acetic acid (48 ml) and cyclohexanone B-11 (5.0 g, 5.3 ml) are added to a 500 ml flask in the order given above. The solution Is stirred for 45 min, and sodium cyano-borohydride (3.2 g) is added portion-wise. The solution is stirred overnight and then concentrated in vacuo. A solution of 20% sodium hydroxide is added to bring the residue to pH 12. Chloroform (45 ml) is also added to dissolve the solids. The organic layer is removed, and the aqueous layer is extracted with chloroform (3 X 40 ml). The organic layers are combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed elutlng with chloroform/methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo. The residue (9.523 g) is distilled bulb to bulb (b0.95 155-165ºC), yielding the title product (6.75 g) as a colorless liquid.
Physical characteristics are as follows: 1H NMR (CDCl3): δ 1.00-1.30, 1.41, 1.63, 1.74, 1.89, 2.35-2.45, 2.47-2.61, 2.67-2.79.
13C NMR (CDCI3) ppm: 57.2, 56.8, 54.3, 44.04, 39.5, 33.3, 25.8, 24.8; IR (neat) 3356, 3281, 2927, 2852, 1641, 1587, 1463, 1451 cm-1. MS for C12H28N4, (m/e): 229, 198, 194, 181, 167, 126, 116, 99. Anal. Found: C, 61.52; H, 12.63; N, 23.71. Water analysis: 5.52%. Example 13 N'-Cyclohexyl-N,N-bis[(2-cyclohexylamlno)ethyl]- 1,2-ethanediamine (Formula B-13). Refer to Chart
B (Scheme 4). Amine B-2 (3.7 ml), methanol (180 ml), aeetic acid (12 ml) and cyclohexanone B-11 (10.3 ml) are combined and stirred at room temperature for 0.5 h. Sodium cyano-borohydride (6.2 g) is added and the reaction is stirred at room temperature overnight. The solution is concentrated in vacuo. The residue is taken up in water (100 ml) and adjusted to pH 12 with 20% sodium hydroxide. The solution is then extracted with chloroform (3 X 40 ml). The organic layers are combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed eluting with chloroform, followed by chloroform/methanol (5/2) and finally with chloroform/- methanol/ammonium hydroxide (10/4/1). The appropriate fractions are combined and concentrated In vacuo producing an orange oil which is then distilled bulb to bulb yielding pure title product (6.0 g). Physical characteristics are as follows: b0.40mm: 205-215ºC.
1H NMR (CDCl3): δ 1.00-1.32, 1.60-1.64, 1.71-1.75, 1.85-1.89, 2.36-2.45, 2.54-2.58, 2.66-2.73.
13C NMR (CDCI3) ppm: 57.0, 54.6, 44.6, 33.5, 26.0, 24.9. IR (neat): 3294, 2928, 2853, 1676, 1450, 1132 cm-1.
MS for C24H48N4 (m/e): 393, 292, 291, 280, 268, 208, 194, 181, 167, 126, 112.
Anal. Found: C, 73.31; H, 12.22; N, 14.11. Corrected for 1.25% water. Example 14 N,N-Bis(2-aminoethyl)-N'-1,4-dioxaspiro-4.5-dec- 8-yl-1,2-ethanediamine (Formula B-15). Refer to Chart B (Scheme 5). Amine B-2 (37.44 g) and methanol (480 ml) are cooled in an ice bath during the addition of acetic acid (118.4 ml). Ketone B-14 (20.0 g) is then added and the reaction is stirred 0.5 h. Via Gooch tubing, sodium cyano-borohydride (8.32 g) is added portionwise. After 23 h the reaction is concentrated in vacuo to 130 g of solid. The solid is dissolved in 20% sodium hydroxide (180 ml) and chloroform. The aqueous portion was exhaustively extracted with chloroform (>1000 ml) until little product can be detected in the aqueous layer by TLC. The organic portion is concentrated in vacuo to 36.64 g. This is chromatographed on silicon dioxide (1.5 kg) and eluted with chloroform/methanol/ammonium hydroxide, 10/4/1 to afford impure B-16 (7.1 g) and the title product, (21.9 g). Physical characteristics are as follows:
1H NMR (CDCI3): δ 1.40-2.03, 2.50-2.89, 3.81, 3.93. 13C NMR (CDCI3) ppm: 164.2, 108.4, 64.2, 64.1, 56.1, 55.3, 54.0, 44.5, 39.1, 32.9, 29.7.
IR (neat): 3408, 3350, 3279, 3186, 2941, 2883, 2864, 2819, 2325, 1578, 1467, 1448, 1378, 1104, 1034, 923 cm-1.
MS for C14H30N4O2, (m/e): 256, 252, 239, 184, 170, 141, 116, 99, 87. Example 15 N,,-Bis-2-(1,4-dioxaspiro-4.5-dec-8-ylamino)- ethyl-1,2-ethanediamine (Formula B-16). Refer to Chart B (Scheme 5). Amine B-2 (37.44 g) and methanol (480 ml) are cooled in an ice bath during the addition of acetic acid (118.4 ml. Ketone B-14 (20.0 g) is then added and the reaction is stirred 0.5 h. Via Gooch tubing, sodium cyano-borohydride (8.32 g) is added portionwise. After 21 h the reaction is concentrated in vacuo. The solid is dissolved in enough 20% sodium hydroxide (-120 mL) to bring the pH to 7. The aqueous portion is extracted with chloroform (3 × 100 ml) and the organic portion is concentrated in vacuo to 22.0 g. This is chromatographed on silicon dioxide (700 g) and eluted with chloroform/methanol/ammonium hydroxide (10/4/1) to yield the title product (7.2 g).
Physical characteristics are as follows: 1H NMR (CDCl3): δ 1.37-2.00, 1.93, 2.48-2.82, 3.93.
IR (neat): 3361, 3290, 3220, 2940, 2883, 2813, 1461, 1447, 1377, 1104, 1035, 922 cm-1.
MS for C22H42N4O4, (m/e): 396, 256, 244, 184, 170. Chemical Ionization (ammonia) MS for C22H42N4O4: 427. Example 16 N ,N-Bis(2-aminoethyl)-N'-cyclohexadecyl-1,2- ethanediamine (Formula B-18). Refer to Chart B (Scheme 6). The ketone B-17 (6.7 ml), toluene (435 ml), amine B-2 (13.0 ml) and p-toluenesulfonic acid (1.1 g) are combined and heated to reflux. The solution Is heated at reflux with azeotropic removal of water for 36 h. The solution is concentrated in vacuo. The residue is taken up in absolute ethanol (200 ml) and hydrogenated over 10% Pd/C (2.0 g) at 50 psi for 2 d. The reaction mixture is filtered through a celite pad, and the pad is washed with ether. The filtrate is concentrated in vacuo and the residue is chromatographed eluting with chloroform/methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo yielding a pale green oil. Solvent traces are removed under high vacuum yielding the title product (3.1 g). Physical characteristics are as follows:
1H NMR (CDCI3): 8 1.31, 1.39-1.48, 2.15, 2.57, 2.61-2.69, 2.77. 13C NMR (CDCI3) ppm: 57.3, 56.9, 54.5, 45.1, 39.7, 32.2, 27.3, 26.9, 26.4, 26.2, 23.5. IR (neat): 3357, 3286, 2929, 2857, 1640, 1461 cm"1. HI RES MS for C22H48N4 Found: 369.3940; m/e: 369, 368, 350, 338, 266, 252, 116, 99, 44).
Example 17 12-[N',N'-bis(2-aminoethyl)-N-l,2-ethanediaminyl]octadecylamide (Formula B-20). Refer to Chart
B (Scheme 7).
The amide B-19 (4.9 g) is added to a stirred solution of the amine B-2 (5.0 ml) and acetic acid (15.8 ml) in methanol (60 ml).
The resulting yellow suspension is stirred at room temperature for 1 h. Sodium cyano-borohydride (1.05 g) is added portionwise and the solution is stirred overnight at room temperature. The solution is concentrated in vacuo, and the residue is taken up in water (a small amount of chloroform is added to dissolve material that does not dissolve in water). The solution is adjusted to pH 12 with 20% sodium hydroxide. The organic layer is removed, and the aqueous layer is extracted with chloroform (3 X 125 ml). The organic layers are combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed (silicon dioxide) eluting with chloroform/methanol/ammonium hydroxide (10/4/1). The appropriate fractions are combined and concentrated in vacuo . Solvent traces are removed under high vacuum yielding the title product (3.96 g) as an orange-brown oil.
Physical characteristics are as follows:
1H NMR (CDCl3): δ 0.88, 1.27, 1.29-1.38, 1.63, 1.90, 2.22, 2.46, 2.53, 2.61-2.66, 2.77, 5.74.
13C NMR (CDCI3) ppm: 176.0, 57.9, 56.6, 54.0, 44.6, 39.5, 35.7, 33.2, 31.7, 29.7, 29.4, 29.3, 29.0, 25.6, 25.4, 22.5, 13.9.
IR (neat): 3355, 3300, 2925, 2853, 1672, 1625, 1466 cm-1. HI RES MS for C24H53N5O, Found: 428.4315; m/e: 428, 427, 411, 385, 366, 355, 339, 327, 313, 299.
Example 18 Methyl 14-[N',N'-bis(2-aminoethyl)-N-1,2-ethanediaminyl]eicosanoate (Formula B-22). Refer to
Chart B (Scheme 8).
The ketone B-21 (5.0 g) is added to a stirred solution of the amine B-2 (4.4 ml) and acetic acid (13.8 ml) in methanol (52.5 ml).
The resulting yellow suspens ion is stirred at room temperature for 1 h. Sodium cyano-borohydride (0.925 g) is added portionwise and the solution is stirred overnight at room temperature. The solution is concentrated in vacuo. The residue is taken up in water (a small amount of chloroform is added to dissolve material that does not dissolve in water) and adjusted to pH 12 with 20% sodium hydroxide. The organic layer is removed, and the aqueous layer is extracted with chloroform (3 X 125 ml) . The organic layers are combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed (silicon dioxide) eluting with chloroform/-methanol/ammonium hydroxide (10/4/1). The appropriate fractions are combined and concentrated in vacuo. Solvent traces are removed under high vacuum producing the very viscous, green oily title product (3.38 g).
Physical characteristics are as follows: 1H NMR (CDCl3): δ 0.88, 1.26, 1.38, 1.55-1.68, 2.10, 2.30, 2.41-2.49, 2.52, 2.59-2.65, 2.77, 3.67. 13C NMR (CDCI3) ppm: 174.0, 58.0, 54.5. 45.0, 39.5, 36.5, 36.0, 34.0, 31.9, 29.7, 25.8, 22.7, 14.1.
IR (neat): 3286, 2925, 2926, 2854, 1742, 1650, 1552, 1466 cm-1. HI RES MS for C27H58N4O2, Found: 471.4603; m/e: 471, 439, 408, 354, 336, 140, 85, 69, 55, 44. Example 19 N,N-Bis(2-aminoethyl)-N'-hexadecyl-1,2-ethanediamine (Formula C-3: wherein R1 is CH3-(CH2)14-). Refer to Chart C. The amine C-2 (3.7 ml), toluene (123 ml), and aldehyde C-1 (wherein R1 is CH3-(CH2)14-) (3.0 g), are combined in a 250 ml flask and stirred over molecular sieves for 3 d. The reaction mixture is filtered and the filtrate concentrated in vacuo producing a green residue. An NMR spectrum of this residue reveals that the aldehyde is no longer present. The green residue (6.04 g) is dissolved in ethanol (125 ml) and hydrogenated over 10% Pd/C (0.60 g) at 50 psi overnight. The reaction mixture is filtered through a celite pad, and the pad is washed several times with diethyl ether. The filtrate is concentrated in vacuo producing a yellow oil (5.86 g). The residue is chromatographed eluting with chloroform/methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo yielding the product as an off-white foam. Solvent traces are removed under high vacuum affording the title product (1.13 g).
Physical characteristics are as follows: 1H NMR (CDCI3): δ 0.89, 1.28, 1.45-1.55, 1.92, 2.52, 2.59-2.66, 2.68-2.75, 2.79.
13C NMR (CDCI3) ppm: 57.3, 54.1, 50.0, 47.6, 39.7, 31.9, 30.0, 29.7, 29.3, 27.4, 22.7, 14.1. IR (mineral oil mull): 3408, 3282, 2739, 1572, 1366, 1307 cm-1 MS (m/e): 370, 340, 323, 309, 268, 254, 116, 99. Anal Found. C, 71.61; H, 13.59; N, 15.08 (corrected for 2.33% water).
Example 20 N,N-bis(2-aminoethyl)-N'-octyl-1,2-ethanediamine (Formula C-2: wherein R1 is CH3- (CH2)6-). Refer to Chart C.
Octanal C-1 (wherein R1 is CH3-(CH2)6-) (5.0 g), amine C-2 (11.7 ml) and p-toluenesulfonic acid (0.5 g) are dissolved in toluene (400 ml) and heated to reflux with azeotropic removal of water for 18 h. The solution is cooled to room temperature and concentrated in vacuo.
The residue is dissolved in absolute ethanol (200 ml) and hydrogenated over 10% Pd/C at 50 psi for 48 h. The reaction mixture is filtered through a Celite pad, and the pad is washed with diethyl ether. The filtrated is concentrated in vacuo producing a yellow residue. The residue is chromatographed eluting with chloroform/-methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo yielding a yellow-green oil.
Solvent traces are removed under high vacuum producing the title product (2.89 g). Physical characteristics are as follows: 1H NMR (CDCI3): δ 0.88, 1.27, 1.45-1.55, 2.42, 2.52-2.59, 2.61-2.64, 2.69-2.73, 2.75-2.80.
13C NMR (CDCI3) ppm: 57.0, 53.9, 49.8, 47.3, 39.5, 31.7, 29.7, 29.3, 29.1, 27.2, 22.5, 13.9. IR (neat): 3350, 3289, 2955, 2826, 1636, 1574, 1468, 1309 cm-1.
MS (m/e): 228, 211, 156, 142, 128, 116, 99. Example 21 N,N-Bis-(2-aminoethyl)-N'-phenylmethyl-1,2- ethanediamine (Formula C-3: wherein R1 is phenyl); N-(2-aminoethyl)-N'-(phenylmethyl)-N- (2((phenylmethyl)amino)ethyl-1,2-ethanediamine
(Formula C-4: wherein R1 is phenyl). Refer to Chart C. Benzaldehyde C-1 (wherein R1 is phenyl) (5.0 g) is added to a solution of the amine C-2 (13.0 ml) In toluene (470 ml) and the resulting solution is stirred over molecular sieves for 4 d. The molecular sieves are filtered off and the filtrate concentrated in vacuo to give a green oil. The oil is dissolved in absolute ethanol and hydrogenated over 10% Pd/C at 50 psi overnight. The reaction mixture is filtered through a Celite pad, the pad washed with ether and the filtrated concentrated in vacuo. The residue is chromatographed eluting with chloroform/methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo to give the first title product (6.2 g) as the major product and a small amount of the second title product (1.1 g).
Physical characteristics for the first title product are as follows:
1H NMR (CDCl3): δ 2.03, 2.48, 2.59, 2.67-2.75, 3.79, 7.25-7.33. 13C NMR (CDCI3) ppm: 140.0, 128.1, 127.9, 126.7, 57.0, 53.9, 53.6, 46.5, 39.3.
IR (neat): 3358, 3286, 2942, 2824, 1584, 1494, 1464, 746, 700 cm-1.
MS for C13H24N4, (m/e): 206, 189, 175, 148, 134, 116, 99. Anal. Found: C, 66.11; H, 10.31; N, 23.70.
Physical characteristics for the second title product are as follows : 1H NMR (CDCI3): δ 2.06, 2.45, 2.57, 2.65-2.72, 3.76, 7.24-7.33. 13C NMR (CDCI3) ppm: 140.2, 128.5, 128.2, 127.0, 57.4, 54.3, 54.0, 46.9, 39.7.
IR (neat): 3294, 3243, 3197, 2941, 2819, 1642, 1602, 1494, 1453 cm-1.
MS (m/e): 327, 296, 284, 219, 206, 189, 175, 163, 148, 134, 120, 91. Anal. Found: C, 73.69; H, 9.36; N, 17.11.
Example 22 N,N-bis(2-aminoethyl)-N'-(2-trifluoromethyl)- phenylmethyl)-1,2-ethanediamine (Formula C-3: wherein R1 is O-CF3-C6H4-). Refer to Chart C. The amine C-2 (8.6 ml) is added to a solution of 2-trifluoromethylbenzaldehyde C-1 (wherein R1 is O-CF3-C6H4-) (5.0 g) in toluene (290 ml). p-Toluenesulfonic acid (0.50 g) is added to the resulting solution. The solution is stirred and heated at reflux with azeotropic removal of water overnight. The solution is concentrated in vacuo producing a yellow-orange residue. The residue is dissolved in absolute ethanol (95 ml) and hydrogenated over 10% Pd/C (1.3 g) at 50 psi overnight. The reaction mixture is filtered though a celite pad, the pad is washed with diethyl ether and the filtrate is concentrated in vacuo. The residue was chromatographed eluting with chloroform/-methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo producing a yellow oil. Solvent traces are removed under high vacuum from the title product (5.95 g).
Physical characteristics are as follows: 1H NMR (CDCl3): δ 2.09, 2.50, 2.61, 2.70-2.81, 3.96, 7.35,
7.54, 7.64.
13C NMR (CDCI3) ppm: 138.9, 131.9, 130.2, 128.0, 126.8, 125.7, 124.5, 57.2, 54.3, 49.7, 47.0, 39.6.
IR (neat): 3292, 3242, 2948, 2826, 1609, 1584, 1457, 1314, 1118, 1037, 772 cm-1.
MS for C14H23N4F3 (m/e): 305, 274, 257, 243, 231, 216, 202, 182, 159, 116, 99.
Anal. Found: C, 55.48; H, 7.75; N, 18.07. Example 23 N,N-bis(2-aminoethyl)-N'-[2-([(1,1'-biphenyl)-4- ylmethyl]amino)ethyl]-1,2-ethanediamine (Formula
C-3: wherein R1 is C6H5-C6H4-). Refer to Chart C. The amine C-2 (8.2 ml), 4-phenylbenzaldehyde C-1 (wherein R1 is C6H5-C6H4) (5.0 g), and p-toluenesulfonic acid (0.5 g) are dissolved in toluene (280 ml) and heated to reflux overnight with azeotropic removal of water. The solution is cooled to room temperature and concentrated in vacuo. The residue is dissolved in absolute ethanol (90 ml) and hydrogenated over 10% Pd/C (1.3 g) at 50 psi for 3 h. The reaction mixture is filtered through a Celite pad, the pad washed with ether and the filtrated concentrated in vacuo. The residue is chromatographed (silicon dioxide) eluting with chloroform/methanol/-ammonium hydroxide, 10/4/1 . The appropriate fractions are combined and concentrated in vacuo, and solvent traces are removed under high vacuum yielding the title product as a yellow oil (5.45 g). Physical characteristics are as follows:
1H NMR (CDCI3): δ 2.35, 2.49, 2.59, 2.68-2.81, 3.88, 7.28-7.49, 7.53-7.59.
13C NMR (CDCI3) ppm: 140.7, 139.7, 139.2, 128.7, 128.6, 128.5, 127.0, 127.0, 126.9, 125.8, 56.8, 54.1, 53.3, 46.8, 39.6.
IR (neat): 3360, 3295, 3055, 3028, 2890, 2830, 1600, 1487, 1451 cm-1.
HI RES MS Found: 313.2392; (m/e): 313, 312, 294, 282, 167, 127, 116.
Example 24 N,N-bis(2-aminoethyl)-N'-N-(2[[[3,4-bis(phenylmethoxy)phenyl]methyl]amino(ethyl-1,2-ethanediamine (Formula C-3: wherein R1 is (Benzyl- O)2C6H3-). Refer to Chart C. The amine C-2 (4.2 ml), 3,4-dibenzyloxybenzaldehyde C-1 (wherein R1 is (Benzyl-0-)2C6H3-) (4.5 g), and p-toluenesulfonic acid (0.45 g) are dissolved in toluene (144 ml) and heated to reflux overnight with azeotropic removal of water. The solution is cooled to room temperature and concentrated in vacuo. The residue is taken up in a small amount of absolute ethanol (15 ml). This solution is added dropwise to a solution of sodium borohydride (2.2 g) in absolute ethanol (130 ml). The reaction is stirred for 24 h, quenched with water (90 ml) and stirred for an additional 0.5 h. The reaction mixture is extracted with chloroform (3 X 90 ml) . The organic layers are combined dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed (silicon dioxide) eluting with chloroform/methanol/ammonium hydroxide, 10/4/1. The appropriate fractions are combined and concentrated in vacuo yielding the title product as a green-yellow oil (1.81 g). Physical characteristics are as follows:
1H NMR (CDCl3): δ 2.37, 2.47, 2.56, 2.61, 2.73, 3.69, 5.13, 5.15, 6.78-6.96, 7.26-7.45.
13C NMR (CDCI3) ppm: 149.0, 148.0, 137.3, 133.2, 129.0, 128.3, 127.6, 127.2, 127.2, 126.1, 121.1, 115.2, 115.0, 71.3, 71.1, 56.7, 53.9, 53.2, 46.5, 39.5.
IR (neat): 3472, 3446, 3357, 3286, 3063, 2934, 2821, 1605, 1590, 1511, 1454, 1424 cm-1.
HI RES MS Found: 448.2840; (m/e): 449, 431, 418, 401, 389, 363, 345, 323, 303, 211, 181, 116, 91. Example 25 N'[2-Bis-(2-aminoethyl)-(amlnoethyl)octadecanamide (Formula D-3) and N,N'-[[(2-aminoethyl- ) imino)dii -2,1-ethanediyl]bis-octadecanamide (Formula D-4). Refer to Chart D (Scheme 1). The amine D-2 (2.92 g) and methyl octadecanoate D-1 (2.98 g) are heated on a steam bath, under nitrogen, for 24 h. The resulting solid is heated in water and is then filtered to remove excess amine. The solid is chromatographed on silicon dioxide (40 g), eluting first with methanol/chloroform, followed by chloroform/methanol/ammonium hydroxide, 10/4/1. The diamide D-4 (0.66 g) elutes first followed by the amide D-3 (1.89 g).
Physical characteristics for the first title product are as follows : 1H NMR (CDCl3): δ 0.88, 1.25, 1.61, 2.16, 2.52-2.61, 2.78, 3.31, 7.10-7.18.
IR (mineral oil mull): 3306, 2907, 1643, 1551, 1471 cm-1. Physical characteristics for the second title product as are follows: 1H NMR (CDCI3): 5 0.88, 1.25, 1.55-1.68, 2.07, 2.52, 2.58, 2.73, 3.26-3.87, 6.71-6.80.
IR (mineral oil mull): 3297, 3079, 2919, 1637, 1557, 1467, 1367 cm-1.
Example 26 N[2-[-bis(2-aminoethyl)amino]ethyl]benzamide (Formula D-13); and N,N'-(((2-aminoethyl)imino)- di-2,1-ethanediyl)bis-benzamide (Formula D-14). Refer to Chart D (Scheme 5). Benzoic anhydride (5.0 g) is dissolved in methylene chloride (250 ml) and the mixture is added dropwise to a stirred solution of the amine D-2 (6.6 ml) in methylene chloride (850 ml) over a period of 50 min. The solution is allowed to warm to room temperature and is stirred overnight. After 16 hr, a small amount of white precipitate forms. The solution is concentrated in vacuo. The residue is dissolved in water and adjusted to pH 12 with 20% sodium hydroxide. The solution is extracted with chloroform (7 X 100 ml). The organic layers are combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue is chromatographed (silicon dioxide) eluting with chloroform/methanol/ammonium hydroxide, 10/4/1. The less polar fractions are combined and concentrated in vacuo to yield the bis adduct as a green oil. Solvents traces are removed under high vacuum affording the second title product (0.52 g).
Physical characteristics of the second title product are as follows: 1H NMR (CDCI3) : δ 1.80 , 2.60 , 2.74- 2.81, 3.55 , 7.24-7.29 , 7.38-7.43 , 7.55 , 7.70-7.73.
IR (neat): 3299, 3030, 2939, 2870, 1639, 1603, 1577, 1545, 1490, 1309, 711 cm-1. HI RES MS Found: 355.2134 (m/e): 355, 354, 324, 220, 191, 177,
148, 105.
The appropriate more polar fractions are combined and concentrated In vacuo. Solvent traces are removed under high vacuum yielding the first title product as a green oil, (2.27 g) . Physical characteristics of the first title product are as follows : 1H NMR (CDCI3): δ 1.98, 2.57, 2.70, 2.77, 3.52, 7.37-7.49, 7.84-7.90, 8.05.
13C NMR (CDCI3) ppm: 167.4, 134.6, 130.9, 128.1, 126.9, 56.6, 52.9, 39.5, 38.2.
IR (neat): 3453, 3350, 3284, 2942, 2820, 1642, 1603, 1578, 1545, 1457, 1309, 711.
HI RES MS Found: 251.1885, (m/e) 252, 251, 250, 232, 220, 208, 191. Example 27 N-(8-aminooctyl)-benzamide (Formula D-11) and
N,N'-1,8-octanediylbis-benzamide (Formula D-12). Refer to Chart D (Scheme 4). A solution of benzoic anhydride D-9 (1.00 g) In methylene chloride (110 ml) is added dropwise to a vigorously stirred solution of the amine D-10 (1.27 g) in methylene chloride (330 ml) at -78ºC over a period of 45 min. The resulting suspension is allowed to stir at room temperature overnight. The reaction mixture is extracted with 5% aqueous hydrochloric acid (2 X 300 ml). The organic layers are combined and concentrated in vacuo producing a white solid which cannot be further purified due to its insolubility. The HCl layer is adjusted to pH 11 with ammonium hydroxide and extracted with methylene chloride (3 X 300 ml). The organic layers are combined and concentrated in vacuo producing an off-white solid which is chromatographed eluting with chloroform/methanol/ammonium hydroxide, 20/8/1. A small amount of the second title product (0.068 g) is isolated off the column.
Physical characteristics of the second title product are a follows: 1H NMR (CDCI3): δ 1.37, 1.54-1.70, 6.15, 7.43-7.49, 7.74-7.77. IR (mull): 3323, 2953, 1631, 1532, 1489, 1476, 1083, 645, 616 cm-1.
HI RES MS Found: 352.2135 (m/e) 352, 247, 231, 218, 204, 190, 148, 135, 105.
The subsequent fractions are combined and concentrated in vacuo yielding the white solid, (0.52 g).
Physical characteristics of the first title product are as follows: Mp: 120-125ºC.
1H NMR (CDCI3): δ 1.25-1.50, 1.55-1.70, 2.68, 3.47, 6.12, 7.41-7.50, 7.76.
13C NMR (CDCI3) ppm: 167.0, 134.5, 131.0, 128.3, 126.6, 42.0, 39.8, 33.5, 29.4, 29.1, 29.0, 26.7, 26.5. IR (mull): 3332, 2923, 1632, 1533, 1447 cm-1.
MS (m/e): 248, 232, 219, 204, 190, 176, 162, 148, 135, 114, 105.
Anal. Found: C, 72.15; H, 10.02; N, 11.27 (corrected for 1.51% water). Example 28 3,3'[-2-(Cyclododecylamino)ethyl-imino-bis(2,1- ethanediylimino)]-bis-propanenitrile (Formula E- 3). Refer to Chart E (Scheme 1) Alkyl amine E-1 (B-6 of Example B) (5.0 g) and methanol (16 ml) are cooled in an ice bath. Acrylonitrile E-2 (2.1 ml) is added at 0.3 ml/min. After 3 hr the reaction is complete and the contents of the flask are concentrated in vacuo to 7.22 g. This is chromatographed on silicon dioxide (200 g) eluting first with methanol/chloroform, followed by chloroform/methanol/ammonium hydroxide, 10/4/1 to provide a pure fraction of the title product (4.12 g) followed by a less pure fraction (2.0 g).
Physical characteristics for the pure fraction of the title product are as follows:
1H NMR (CDCI3): δ 1.20-1.60, 1.72, 2.5-2.75, 2.93. 13C NMR (CDCI3) ppm: 118.7, 55.1, 54.4, 54.0, 46.7, 45.0, 29.0, 24.8, 24.2, 22.8, 22.8, 20.7, 18.5.
IR (neat): 3306, 2934, 2905, 2247, 1470, 1132, 1061 cm-1. MS (m/e) 335, 278, 265, 222, 196, 152, 140. Chemical Ionization (ammonia) MS: 419. Anal. Found: C, 68.94; H, 11.34; N, 19.86.
Example 29 N,N'(2-(Cyclododecylamino)ethyl-imino-di-2,1- ethanediyl)-bis-1,3-propanediamlne (Formula E-4).
Refer to Chart E (Scheme 1). A solution of dinitrile, the title product of Example 28 (2.92 g) and tetrahydrofuran (5 ml) Is added to a cooled (0ºC) mixture of lithium aluminum hydride (1.06 g) and tetrahydrofuran (25 ml). The reaction is warmed to room temperature and stirred for 6 hr.
Ammonium chloride (20 ml) is used to quench the reaction and 20% sodium hydroxide is used to bring the mixture to pH 12. The aluminum salts are removed by filtration and the filtrate is extracted with chloroform (3 x 150 ml) . The organic layers are combined, dried, and concentrated to provide the title product (3.3 g).
Physical characteristics of the title product are as follows: 1H NMR (CDCI3): δ 1.20-1.70, 2.50-2.90.
13C NMR (CDCI3) ppm: 55.1, 54.9, 54.4, 47.8, 45.6, 40.4, 33.9,
29.2, 25.0, 24.4, 22.9, 22.8, 20.7.
IR (neat heated): 3286, 2930, 1634, 1598, 1470, 1446, 1125 cm- 1 Chemical Ionization (isobutylene) MS (m/e): 427.
Example 30 N,N'(2-(Cylododecylamino)ethyl-imino-di-2,1- ethanediyl)-bis-betaalanine, dimethyl ester
(Formula E-6). Refer to Chart E (Scheme 2).
At 0ºC alkyl amine E-1(B-6) of Example 8 (3.12 g), methanol (10 ml), and methyl acrylate (1.8 ml), (172 g) are combined. After 1 hr the reaction has warmed to room temperature, and the reaction is continued for an additional 5 hr at room temperature. Concentration of the reaction in vacuo leaves an oil which is chromatographed on silicon dioxide (150 g) and eluted with methanol/chloroform, followed by chloroform/methanol/ammonium hydroside (10/4/1). Combination of the appropriate fractions yields the title product (3.29 g).
Physical characteristics of the title product are as follows: 1H NMR (CDCI3): 8 1.20-1.60, 2.13, 2.40-2.74, 2.88, 3.68. 13C NMR (CDCI3) ppm: 173.1, 55.2, 54.6, 54.2, 51.4, 47.3, 45.1, 45.0, 34.3, 29.0, 25.0, 24.4, 22.9, 22.85, 20.7.
IR (neat): 3306, 2934, 1739, 1663, 1470, 1443, 1438, 1196, 1177 cm-1.
MS (m/e): 485, 453, 411, 368, 288, 276, 173. Anal. Found: C, 64.19; H, 10.81; N, 11.76 (corrected for 1.9% water).
Example 31 1-Amino-N-(2-aminoethyl)-10-[2-cyclododecylamino)ethyl]-4-oxo-3,7,10,13-tetraazahexadecan- 16-amide (Formula E-7). Refer to Chart E (Scheme
2).
Ethylene diamine (49.4 g) is added to a solution of the title product of Example 30 (5.0 g) in methanol (105 ml). The reaction is stirred at room temperature for 4 days. The solution is concentrated in vacuo and solvent traces are removed under high vacuum producing the title product as a green oil (4.39 g).
Physical characteristics of the title product are as follows: 1H NMR (CDCl3): δ 1.35, 1.48-1.55, 1.61, 2.35-2.45, 2.59, 2.67, 2.75-2.89, 3.25-3.38, 7.80. 13C NMR (CDCI3) ppm: 172.8, 55.1, 54.7, 54.1, 47.2, 45.7, 45.0, 41.9, 41.4, 35.8, 29.2, 24.9, 24.3, 22.9, 22.8, 20.7. Example 32 N-Cyclododecyl-N',N'-bis-2-(dimethylamino)ethyl- N-methyl-1,2-ethanediamine (Formula F-3). Refer to Chart F (Scheme 2). The alkyl amine F-1 (B-6) of Example 8 (5.0 g) is cooled to 0°C and formic acid (6.2 g) is added, followed by formaldehyde (9.1 g).
The reaction is heated to 80ºC with vigorous evolution of gas. After continuing the reaction overnight, the material is concentrated in vacuo. The residue is brought to pH 12 with 10% sodium hydroxide. The aqueous portion is extracted with chloroform (3 × 50 ml), dried and concentrated to 6.0 g. Bulb to bulb distilled of the liquid afforded pure title product (5.29 g).
Physical characteristics of the title product are as follows: Bp: 160-180 ºC at 0.1 mm. 1H NMR (CDCI3): δ 1.22-1.52, 2.24, 2.32-2.66.
13C NMR (CDCI3) ppm: 57.6, 57.4, 53.9, 52.9, 51.3, 45.7, 37.9, 25.3, 23.7, 23.6, 23.4, 22.4, 22.3.
IR (neat): 2938, 2907, 1691, 1469, 1265, 1123, 1042 cm-1. MS (m/e): 324, 224, 223, 210, 172, 160, 129, 72. Anal. Found: C, 72.00; H, 13.22; N, 14.88.
Example 33 2,2'-[2-(Cyclododecylmethylamino)ethyl-imino]- bis-N,N,N-trimethylethanaminium diiodide (Formula F-4). Refer to Chart F (Scheme 2). The title product of Example 32 (1.0 g) and acetonitrile (250 ml) are combined. Methyl iodide (740 mg) in acetonitrile (1 ml) is added to the reaction. After 14 hr, a white solid is present In the flask. The contents of the flask are concentrated in vacuo to yield 1.67 g of the title product.
Physical characteristics of the title product are as follows: 1H NMR (CDCl3): δ 1.01-1.30, 2.03, 2.30-2.42, 2.50-2.60, 2.72-2.86, 3.03, 3.24, 3.72.
13C NMR (CDCI3) ppm: 61.6, 58.0, 52.8, 51.3, 50.6, 46.7, 37.5, 24.9, 23.5, 23.4, 23.0, 22.2.
IR (mineral oil mull): 3475, 2922, 2856, 1468, 1377, 947, 918 cm-1.
MS (m/e): 667, 539, 397, 338, 224, 58. Anal. Found: C, 45.10; H, 8.63; N, 8.46. Example 34 N',N'bis-2-(Dimethylamino)ethyl-N-1,4-dioxaspiro- 4.5-dec-8-yl-N-methyl-1,2-ethanediamine (Formula
F-6). Refer to Chart F (Scheme 2).
To a flask equipped with an overhead stirrer amine F-5 is added
(3.05 g) and cooled to 0ºC. Formic acid (4.1 g, 95% pure) and formaldehyde (6.2 g, 36% in aq. sol.) are added. The reaction is heated to 80ºC for 22 hr with evolution of carbon dioxide. The contents of the flask are concentrated in vacuo and are then made basic (pH = 12) with 20% sodium hydroxide (10 ml). The aqueous portion is extracted with chloroform (3 × 10 ml) and concentration of the organic portions yields 3.61 g of crude product. The crude material is bulb to bulb distilled in a kugelrohr oven to afford the title product (2.25 g).
Physical characteristics of the title product are as follows: Bp: 160-180°C at 0.1 mm. 1H NMR (CDCI3): δ 1.50-1.66, 1.69-1.85, 2.24, 2.26, 2.35-2.68, 3.93.
IR (neat): 2943, 2816, 2766, 1463, 1106, 1033, 927 cm-1. MS (m/e): 298, 198, 184, 172, 129, 72. Anal. Found: C, 63.80; H, 11.50.
TABLE 1
Serum lipoprotein cholesterol in SEA quail fed 0.5% cholesterol-1% peanut oil: Effect of bile acid binding compounds
Example # of Compound Dose No. of Serum Cholesterol (mg/dl) Tested mg/kg/day animals Alpha Beta Total
Normal Diet - - 10 156 55 218
Cholesterol/Peanut - - 19 170 264 444 Oil Diet - - 17 218 252 492 - - 20 218 276 519
Colestipol 500 10 200 184 405 hydrochloride 750 10 165 138** 321*
750 10 201 122* 327*
1000 10 210 129* 366
2000 10 222 61** 287**
2250 10 150 83** 239**
Example 7 150 10 162 77** 243** (1st cpd.) 10 10 239 299 567 30 10 243 325 590 100 10 280* 191 481 300 10 194 60** 256** 150 10 179 80** 264**
Example 8 150 10 209 166 415 30 10 273 332 638 100 10 279 166 455 300 10 219 65** 289** 200 10 205 116** 326
Example 10 150 10 187 240 440
Example 7 150 10 182 95** 281** (2nd cpd.)
Example 12 150 10 215 368 598-I
Example 14 150 10 187 337 531-I
Example 32 150 7 82** 51** 137**
Example 15 25 10 202 546 776-I
Example 9 25 10 215 172 407
150 10 162 85** 251**
10 10 192 263 483 TABLE 1 (continued)
Serum lipoprotein cholesterol in SEA quail fed 0.5% cholesterol-1% peanut oil: Effect of bile acid binding compounds
Example # of Compound Dose No. of Serum Cholesterol (mg/dl) Tested mg/kg/day animals Alpha Beta Total
Example 9 (cont'd) 25 10 211 322 555
50 10 202 135** 347*
100 10 176* 70** 247* Example 33 150 10 224 144 379
Example 19 100 10 213 142 361
Example 11 25 10 203 301 511
50 9 209 216 438
100 10 224 131** 368*
10 10 193 235 441
Example 29 150 10 206 130 354
Example 22 50 10 222 212 455
Example 21 150 10 203 327 562-I (1st cpd.)
Example 17 50 10 191 185 387
Example 18 50 10 223 251 490 Example 23 100 10 206 173 398
Example 13 150 10 226 180 437
* and ** significantly different from cholesterol/peanut oil diet controls
*P = 0.006 **P = 0.001 -I = inactive TABLE 2
Serum lipoprotein cholesterol in rats fed 1% cholesterol: Effect of bile acid binding compounds
Compound Dose No. of Serum Cholesterol (mg/dl) mg/kg/day Animals Alpha Beta Total
Normal Diet - - - 10 84 21 105
Cholesterol - - - 20 70 56 129
Diet - - - 20 64 66 131
- - - 20 60 73 135
Colestipol 500 10 67 36 104 hydrochloride 500 10 70 41 113
1000 10 72 25 98
1000 10 72 29 102
N,N-bis(2-amino150 10 48* 31** 81 ethyl)-N'-cyclopentadecyl-1,2- ethanediamine
N,N-bis[2-cyclo3 10 57 93 155 dodecylamino)- 10 10 57 76 135 ethyl]-1,2-ethane30 10 58 58 125 diamine 60 10 39** 43** 84**
100 10 45** 53 102*
* and ** significantly different from cholesterol diet *P=0.006 **p=0.001
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification 4 : (11) International Publication Number: WO 89/ 080 C07C 87/34, A61K 31/13 C07C 87/36, 87/28, 87/451 C07C 93/02, 93/14, 101/26 C07C 103/82, 103/87, 103/183 A3 C07C 103/50, 12/43 C07D 317/72, A61K 31/16 A61K 31/22, 31/195, 31/275 (43) International Publication Date: 8 September 1989 (08.09. A61K 31/335
(21) International Application Number: PCT/US89/00490 (72) Inventors; and
(75) Inventors/Applicants (for US only) : AIKEN, James,
(22) International Filing Date: 13 February 1989 (13.02.89) [US/US]; 357 Shangri-la Circle, Plainwell, MI 490 (US). SPILMAN, Charles, H. [US/US]; 9944 Spri wood Drive, Kalamazoo, MI 49001 (US). THOM
(31) Priority Application Number : 158,213 Edward, W. [US/US]; 901 Wilshire Blvd., Kala zoo, MI 49001 (US).
(32) Priority Date: 19 February 1988 (19.02.88)
(74) Agent: COX, Martha, A.; Patent Law Department, T
(33) Priority Country : US Upjohn Company, Kalamazoo, MI 49001 (US).
(81) Designated States: AT (European patent), AU, BE (
(60) Parent Application or Grant ropean patent), CH (European patent), DE (Eu
(63) Related by Continuation pean patent), DK, FI, FR (European patent),
US 158,213 (CIP) (European patent), IT (European patent), JP, KR,
Filed on 19 February 1988 (19.02.88) (European patent), NL (European patent), NO, (European patent), US. Published
(71) Applicant (for all designated States except US): THE With international search report UPJOHN COMPANY [US/US]; 301 Henrietta Street, Before the expiration of the time limit for amending th Kalamazoo, MI 49001 (US). claims and to be republished in the event of the receipt o amendments.
(88) Date of publication of the international search report:
2 November 1989 (02.11.89
(54) Title: LIPOPHILIC POLYAMINES USEFUL FOR TREATING HYPERCHOLESTEROLEMIA
(57) Abstract
This invention relates to novel lipophilic polyamides of the formula Z]-(CH )n-Yι-Xι-R], the method of using the compounds to treat hypercholesterolemia, and intermediates thereto.
FOR THE PURPOSES OF INFORMAΩON ONLY
Codes used to identify States party to the PCT on the front pages of pamphletspublishing international applications under the PCT.
AT Austria FR France ML Mali
All Australia GA Gabon MR Mauritania
BB Barbados GB United Kingdom MW Malawi
BE Belgium HU Hungary NL Netherlands
BG Bulgaria IT Italy NO Norway
BJ Benin JP Japan RO Romania
BR Brazil KP Democratic People's Republic SD Sudan
CF Central African Republic of Korea SE Sweden
CG Congo KR Republic of Korea SN Senegal
CH Switzerland LI Liechtenstein Sϋ Soviet Union
CM Cameroon LK Sri Lanka TD Chad
DE Germany, Federal Republic of LU Luxembourg TG Togo
DK Denmark MC Monaco US United States of America
El Finland MG Madagascar

Claims (8)

1. A compound of the formula I Z1-(CH2)n-Y1-X1-R1 I wherein Z1 is
(a) -C3-C20-cycloalkyl substituted with zero or one =0,- C(O)OR11, -C(O)NH2, -CH-CH2-, or ethylene ketal;
(b) -C3-C20-alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -alkyl(C1-C12)-cycloalkyl(C3-C8);
(d) -benzyl substituted with zero, one, or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, - phenyl or -benzyl-oxy; or
(e) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or benzyl-oxy; wherein Y1 is
(a) -C(O)-, or
(b) absent; wherein X1 is (a) -NR2- ,
(b) -NR2R3, or
(c) -N(R2)2R3X4; wherein X4 is a pharmaceutically acceptable anion; wherein R1 is (a) -H,
(b) -C1-C4alkyl,
(c) -benzyl,
(d) -(CH2)p-N(R4)(R5),
(e) -(CH2)p-N(R4)-Y1-R5, or (f) when X1 is -NR2R3 or -N(R2)2R3X4, R1 is absent; wherein R2 is
(a) -H,
(b) -C1-C6alkyl,
(c) -(CH2)m-N(R4)(R5), (d) -(CH2)m-N(R4)-Y1-R5,
(e) -(CH2)m-O-(CH2)m-N(R4)(R5), or
(f) -(CH2)m-NH-C(NH)-NH2; or when X1 is -NR2-, wherein R1 and R2 taken together cab be -(CH2)q- X3-(CH2)q-; wherein R3 is
(a) -CH3, or
(b) =0; wherein R4 is
(a) -H,
(b) -C1-C6alkyl,
(c) -benzyl,
(d) -phenyl, (e) -(CH2)q-N(R6)(R7),
(f) -(CH2)q-N(R6)-Y1-R7 or
(g) -(CH2)q-N(R6)3X4; wherein R5 is (a) -H, (b) -C1-C6alkyl,
(c) -(CH2)r-N(R8)(R9),
(d) -(CH2)r-N(R8)-Y1-R9, or
(e) -(CH2)r-N(R8)3X4; or wherein R4 and R5 taken together are - (CH2)q-X2- (CH2)q- ; wherein R6, R7 , R8, or R9 is each independently
(a) -H,
(b) -C3-C20cycloalkyl substituted with zero or one =0 ,- C(O)OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -C3-C20alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH=CH2, ethylene ketal or C=N;
(d) -alkyl (C1-Cl2) -cycloalkyl (C3-C8),
(e) -benzyl substituted with zero, one, or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or benzyl-oxy;
(f) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(g) -(CH2)s-N(R10)(R11);
(h) -(CH2)s-N(R10)-Y1-R11;
(i) amino acid residue, or
(j) -(CH2)s-Het; or wherein R6 and R7 taken together are - (CH2)q-X2- (CH2)q- ; or wherein R3 and R9 taken together are - (CH2)q-X2- (CH2)q- ; wherein R10 or R11 is each independently
(a) -H, (b) -C1-C6alkyl, or
(c) -(CH2)n-NH2; or wherein R10 and R11 taken together are - (CH2)q-X2- (CH2)q- ; wherein X2 is (a) -O-,
(b) -NH-,
(c) -N(CH3)-, or
(d) -N-(CH2)q-NH2; wherein X3 is (a) -O-,
(b) -S-,
(c) -NH-, or
(d) -N(CH3)-; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to three of the following: (i) C1-C6alkyl,
(ii) hydroxy, (iii) trifluoromethyl, (iv) C1-C4alkoxy, (v) halo, (vi) phenyl,
(vii) phenyl C1-C4alkyl-, (viii) amino ,
(ix) mono- or di- (C1-C4alkyl)amino, and (x) C1-C5alkanoyl; wherein n is zero to five, inclusive; wherein m, p, q, r or s is each independently one to ten, inclusive; with the provisos that:
1) If Z1 is C8-C20cycloalkyl, then one of the following must occur : a) R1 is other than -H, C1-C4alkyl, or benzyl; b) R2 is other than -H, -C1-C6alkyl or - (CH2)m-NH-C(NH) - NH2; c) when R1 is - (CH2)p-N(R4) (R5) or when R2 is -(CH2)m- N(R4)(R5) or -(CH2)m-O-(CH2)m-N(R4)(R5), then R4 is other than -H,- C1-C6alkyl, -benzyl, or -phenyl and R5 is other than -H or -C1- C6alkyl; d) when R4 is - (CH2)q-N(R6) (R7) , then R6 and R7 are other than -H, -(CH2)3-NH2; e) R1 and R2 are not taken together; or f) R4 and R5 are not taken together; and 2) If Z1 is C10-C20alkyl, then Y1 is absent.
2. A compound of claim 1 wherein Z1 is C3-C20cycloalkyl or C3-C20alkyl; n is zero; Y1 is absent; X1 is -NR2-; R1 is H; R2 is-(CH2)m-N(R4)(R5) or - (CH2)m-N(R4) -Y1-R5; R4 is - (CH2)q-N(R6) (R7), (CH2)q-N(R6)-Y1-R7, or -(CH2)q-N(R6)3X4; and R5 is - (CH2)r-N(R8) (R9), -(CH2)r-N(R8)-Y1-R9, or - (CH2)r-N(R8)3X4.
3. A compound of claim 2 selected from the group consisting of: 1,2-Ethanediamine, N,N-bis-2-(cyclododecylamino)ethyl-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclododecyl-; 1,2-Ethanediamine, N'-cyclododecyl-N,N-bis-2-(cyclododecylamino)ethyl-.
4. A compound of claim 1 selected from the group consisting of: Benzamide, N-(8-aminooctyl)-;
Benzamide, N,N'-1,8-octanediylbis-; Propanenitrile, 3,3'-[2-(cyclododecylamino)ethylimino-bis(2,1-ethanediylimino)]-bis-; beta.-Alanine, N,N'-[2-(cyclododecylamino)ethylimino-di-2,1-ethanediyl]-bis-, dimethyl ester;
Ethanaminium, 2,2'-[2-(cyclododecylmethylamino)ethyl-imino]-bis-N,N,N-trimethyl-, diiodide;
1,2-Ethanediamine, N,N-bis-2-(dimethylamino)ethy1-N'-1,4-dioxaspiro-4.5-dec-8-yl-N'-methyl-;
Ethanol, 2,2'-2-(cyclododecyloxy)ethyl-imino-bis-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclopentadecyl; 1,2-Ethanediamine, N,N-bis-2-(cyclopentadecylamino)ethyl-;
1,2-Ethanediamine, N,N-bis-2-(cyclododecylamino)ethyl-;
1,2-Ethanediamine, N'-cyclododecyl-N,N-bis-2-(cyclododecylamino)ethyl-; 1,2-Ethanediamine, N'-cyclohexyl-N,N-bis[2-(cyclohexylamino)-ethyl]-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-1,4-dloxaspiro-4.5-dec-8-yl-; 1,2-Ethanediamine, N,N-bis-2-(1,4-dioxaspiro-4.5-dec-8-ylamino)-ethyl-;
Octadecanamide, 12-2-bis(2-aminoethyl)amino-ethyl-amino-; Eicosanoic acid, 14-2-bis(2-aminoethyl)amino-ethyl-amino-, methyl ester; 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-hexadecyl-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-(phenylmethyl)-; 1,2-Ethanediamine, N-(2-amlnoethyl)-N'-(phenylmethyl)-N-[2- [(phenylmethyl)amino]ethyl]-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-[[2-(trifluoromethyl)phenyl]methyl]-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-[2-([(1,1'-biphenyl)-4-ylmethyl]amino)ethyl]-;
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-N-[2-[[[3,4-bis(phenylmethoxy)phenyl]methyl]amino]ethyl]-; Benzamide, N-[2-[bis(2-aminoethyl)amino]-ethyl]-;
Benzamide, N,N'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis; N,N-Bis(2-aminoethyl)-N'-cyclohexadec-8-enyl-1,2-ethanediamine; N,N-Bis (2-aminoethyl)-N'-cyclohexadecyl-1,2-ethanediamine; N,N-Bis(2-aminoethyl)-N'-octyl-1,2-ethanediamine; and 1-Amino-N-(2-aminoethyl)-10-[2-cyclododecylamino)ethyl]-4-oxo- 3,7,10,13-tetra-azahexadecan-16-amide.
5. A compound selected from the group consisting of:
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclododecyl; 1,2-Ethanediamine, N-(2-aminoethyl)-N'-cyclododecyl-; 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclohexyl-;
1,3-Propanediamine, N,N''-[2-(cyclododecylamino)ethylimino-di- 2,1-ethanediyl]-bis-;
1,2-Ethanediamine, N-cyclododecyl-N',N'-bis-2-(dimethylamino)- ethyl-N-methyl-; Octadecanamide, N-[2[bis(2-aminoethyl)amino]ethyl]-; and
Octadecacamide, N,N'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]- bis-.
6. A method of treating hypercholesterolemia in an affected patient which comprises administering to said patient an effective amount for reducing serum cholesterol in said patient of a member selected from the group consisting of the free bases and pharmaceutically acceptable salts of a compound of formula I
Z1-(CH2)n-Y1-X1-R1 I wherein Z1 is
(a) -C3-C20-cycloalkyl substituted with zero or one =0,- C(O)OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(b) -C3-C20-alkyl substituted with zero or one =0, -C(O)OR11,- (O)NH2, -CH=CH2, or ethylene ketal;
(c) -alkyl(C1-C12) -cycloalkyl(C3-C8);
(d) -benzyl substituted with zero, one, or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(e) -phenyl substituted with zero, one or two -C(O)OR11,- C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy; or
(f) a steroid of formula II:
wherein A1 is
(a) -(CH2)4-,
(b) -CH2-CH2-C(O)-CH-, or
(c) -CH2-CH2-CH(E1)-CH2-; wherein D1 is
(a) -hydrogen, or
(b) -methyl; wherein E1 is
(a) -hydrogen, or
(b) -OF1; wherein F1 is
(a) -H,
(b) -C1-C3alkyl, or
(c) -benzyl; wherein Y1 is
(a) -C(O)-, or (b) absent; wherein X1 is
(a) -NR2-,
(b) -NR2R3, or (c) -N(R2)2R3X4; wherein X4 is a pharmaceutically acceptable anion; wherein R1 is
(a) -H,
(b) -C1-C4alkyl, (c) -benzyl,
(d) -(CH2)p-N(R4)(R5),
(e) -(CH2)p-N(R4)-Y1-R5, or
(f) when Xi is -NR2R3 or -N(R2)2R3X4, R1 is absent; wherein R2 is (a) -H,
(b) -C1-C6alkyl,
(c) -(CH2)m-N(R4)(R5),
(d) -(CH2)m-N(R4)-Y1-R5,
(e) -(CH2)m-O-(CH2)m-N(R4)(R5), or (f) -(CH2)m-NH-C(NH)-NH2; or when X^ Is -NR2-, wherein R1 and R2 taken together can be -(CH2)q- X3-(CH2)q-; wherein R3 is
(a) -CH3, or (b) -O; wherein R4 is
(a) -H,
(b) -C1-C6alkyl,
(c) -benzyl, (d) -phenyl,
(e) -(CH2)q-N(R6)(R7),
(f) -(CH2)q-N(R6)Y1R7, or
(g) -(CH2)q-N(R6)3X4; wherein R5 is (a) -H,
(b) -C1-C6alkyl,
(c) -(CH2)r-N(R8)(R9),
(d) -(CH2)r-N(R8)-Y1-R9, or (e) -(CH2)r-N(R8)3X4; or wherein R4 and R5 taken together are - (CH2)q-X2- (CH2)q- ; wherein R6, R7, R8 , or R9 is each independently (a) -H, (b) -C3-C20cycloalkyl substituted with zero or one =0, C(O)-OR11, -C(O)NH2, -CH=CH2, or ethylene ketal;
(c) -C3-C20alkyl substituted with zero or one =0, -C(O)OR11,- C(O)NH2, -CH-CH2, ethylene ketal or C=N;
(d) -alkyl (C1-C12)-cycloalkyl (C3-C8), (e) -benzyl substituted with zero, one, or two -C(O)OR11,-
C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(f) -phenyl substituted with zero, one or two -C(O)OR11,-C(O)NH2, -CH=CH2, -CF3, -phenyl or -benzyl-oxy;
(g) -(CH2)s-N(R10)(R11); (h) -(CH2)s-N(R10)-Y1-R11; (1) amino acid residue; or
(j) -(CH2)s-Het; or wherein R6 and R7 taken together are - (CH2)q-X2- (CH2)q- ; or wherein R8 and R9 taken together are - (CH2)q-X2- (CH2)q- ; wherein R10 or R11 is each independently
(a) -H,
(b) -C1-C6alkyl, or
(c) -(CH2)n-NH2; or wherein R10 and R11 taken together are - (CH2)q-X2- (CH2)q- ; wherein X2 is
(a) -O-,
(b) -NH-,
(c) -N(CH3)-, or
(d) -N-(CH2)q-NH2; wherein X3 is
(a) -O-,
(b) -S-,
(c) -NH-, or
(d) -N(CH3)-; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to three of the following:
(i) C1-C6alkyl, (ii) hydroxy, (iii) trifluoromethyl,
(iv) C1-C4alkoxy,
(v) halo, (vi) phenyl, (vii) phenyl C1-C4alkyl-, (viii) amino,
(ix) mono- or di-(C1-C4alkyl)amino, and (x) C1-C5alkanoyl; wherein n is zero to five, inclusive; wherein m, p, q, r or s is each independently one to ten, inclusive; provided that the compound is other than:
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclohexyl-; 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-l,4-dioxaspiro-4.5-dec-8-yl-;
1,2-Ethanediamine, N,N-bis-2-(l,4-dioxaspiro-4.5-dec-8-ylamino)-ethyl-;
N,N-Bis-(2-aminoethyl)-N'-phenylmethyl-1,2-ethanediamine; 1,2-Ethanediamine, N-(2-aminoethyl)-N'-(phenylmethyl)-N-[2-[(phenylmethyl)amino]ethyl]-; or
N[[2-[-Bis(2-aminoethyl)amino]ethyl]benzamide.
7. A method of claim 6 wherein Z1 is C3-C20cycloalkyl or C3-C20alkyl; n is zero; Y1 is -C(O)- or absent; X1 is NR2; R1 is H; R2 is-(CH2)m-N(R4)(R5) or -(CH2)m-N(R4) -Y1-R5; R4 is -(CH2)q-N(R6) (R7), - (CH2)q-N(R6)-Y1-R7, or -(CH2)q-N(R6)3X4; and R5 is -(CH2)r-N(R8)(R9), -(CH2)r-N(R8)-Y1-R9, or -(CH2)r-N(R8)3X4.
8. A method of claim 7 selected from the group consisting of: 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclopentadecyl-; 1,2-Ethanediamine, N,N-bis-2-(cyclododecylamino)ethyl-; 1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-cyclododecyl-;
1,2-Ethanediamine, N'-cyclododecyl-N,N-bis-2-(cyclododecylamino)ethyl-; and
1,2-Ethanediamine, N,N-bis(2-aminoethyl)-N'-hexadecyl-.
AU32034/89A 1988-02-19 1989-02-13 Lipophilic polyamines useful for treating hypercholesterolemia Abandoned AU3203489A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15821388A 1988-02-19 1988-02-19
US158213 1988-02-19

Publications (1)

Publication Number Publication Date
AU3203489A true AU3203489A (en) 1989-09-22

Family

ID=22567128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32034/89A Abandoned AU3203489A (en) 1988-02-19 1989-02-13 Lipophilic polyamines useful for treating hypercholesterolemia

Country Status (6)

Country Link
EP (1) EP0424385A1 (en)
JP (1) JPH03502796A (en)
KR (1) KR900700433A (en)
AU (1) AU3203489A (en)
DK (1) DK196990D0 (en)
WO (1) WO1989008098A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
DE19605175A1 (en) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipid compounds and their use
FR2802817B1 (en) * 1999-12-23 2002-10-11 Centre Nat Rech Scient NOVEL GLYCOSIDASE INHIBITORS AND THEIR PHARMACOLOGICAL APPLICATIONS, PARTICULARLY FOR TREATING DIABETES
ATE553114T1 (en) * 2005-02-28 2012-04-15 Alphabeta Ab COMPOUNDS FOR REDUCING AGGREGATION OF AMYLOID BETA PEPTIDE
CN104922676B (en) 2009-03-20 2019-03-12 Clsn实验室股份有限公司 Polyamine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1065248A (en) * 1951-04-16 1954-05-21 Ciba Geigy Process for the preparation of novel trialkylamines
EP0243449A1 (en) * 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain

Also Published As

Publication number Publication date
WO1989008098A3 (en) 1989-11-02
DK196990A (en) 1990-08-17
EP0424385A1 (en) 1991-05-02
KR900700433A (en) 1990-08-13
JPH03502796A (en) 1991-06-27
WO1989008098A2 (en) 1989-09-08
DK196990D0 (en) 1990-08-17

Similar Documents

Publication Publication Date Title
US3352912A (en) Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US5192798A (en) Lipophilic polyamines useful for treating hypercholesterolemia
EP1698629A2 (en) Polyamines and their use in therapy
EP0356128A2 (en) 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent
US9598351B2 (en) Polyamine transporter selective compounds as anti-cancer agents
EP0400011A1 (en) New phenylethanolamines.
DD283374A5 (en) PROCESS FOR PREPARING 2-HYDROXY-3-PHENOXYPROPYLAMINO COMPOUNDS
AU2009200639A1 (en) Oligoamine compounds and derivatives thereof for cancer therapy
DE69415657T2 (en) POLYAMINE DERIVATIVES AS A RADIATION PROTECTION AGENT
DE69520430T2 (en) META SUBSTITUTED ARYLALKYLAMINE AND THERAPEUTIC AND DIAGNOSTIC USE THEREOF
AU3203489A (en) Lipophilic polyamines useful for treating hypercholesterolemia
DE69813228T2 (en) ALIFATIC PROPARGYLAMINE AS A CELLULAR RESCUE
US4277471A (en) 1,1-Biphenyl-2-yl alkylamines, formulations and antiarrhythmic treatment
WO1996022962A9 (en) Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
WO1996022962A1 (en) Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
Thomas et al. Cholesterol-lowering bile acid-binding agents: novel lipophilic polyamines
DE2458908C2 (en) Alkanolamine derivatives and pharmaceutical compositions containing them
US4658061A (en) 9-aminoalkylfluorenes
US5770625A (en) Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
EP0491243A1 (en) Alkylaminoalkylamino and -ether compounds as well as processes and intermediates for their preparation, and medicaments containing these compounds
US6593340B1 (en) Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression
FI67364C (en) PHARMACEUTICAL FORM OF PHARMACOLOGICAL ACTIVE 1-PHENYL-2- (PHENOXY-ISOPROPYLAMINO) -1,3-PROPANDIOL
LU82237A1 (en) (1,1-BIPHENYL-2-YL) -PROPYL- AND BUTYLAMINES, THEIR PREPARATIN AND THEIR THERAPEUTIC USE
DE2440755A1 (en) PHENYLAETHYLAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE
DE1593392C3 (en) New amino ethers derived from 9,10-ethano-9,10-dihydroanthracene and their salts and processes for their preparation